Current normal of care for sophisticated head and neck squamous cell carcinoma consists of the anti-PD-1 checkpoint inhibitor pembrolizumab (Keytruda) with or with out chemotherapy (platinum/five-fluorouracil [5-FU]). The INDUCE-1 trial — led by Erminia Massarelli, MD, PhD, a thoracic oncology specialist at City of Hope in Duarte, California — tested the addition of the ICOS-1 antibody GSK609 to these regimens.
Following is a transcript of her remarks:
The background of our trial is essentially, if we could enhance the efficacy of pembrolizumab plus chemotherapy in individuals with head and neck squamous cell carcinoma with PD-L1 [expression] significantly less than 1. And, mostly this is a phase 1 [trial], the toxicity of the association of ICOS-1 antibody plus pembrolizumab and chemotherapy with platinum (either cisplatin or carboplatin, plus five-FU). However, we also presented a further multi-cohort phase 1 clinical trial with pembrolizumab along with chemotherapy — generally as an alternative of the 4-drug regimen, the 3-drug regimen, so the ICOS plus the cisplatin or carboplatin plus five-FU.